UBS upgrades this grocery store chain to buy, sees big gains ahead

UBS upgraded Albertsons (ACI) shares to Buy from Neutral, raising its price target to $27 from $22, implying 35% upside, following a recent 7% share decline. The upgrade is predicated on ACI's significant top-line opportunities from pharmacy cross-shopping and digital, profitability improvements via centralized buying and retail media, and competitive advantages from its market footprint, particularly in high-income areas. Analysts anticipate consistent financial beats and share repurchases, which should narrow the valuation gap with peers like Kroger and boost private label penetration, supporting gross margins.

Analysis

UBS has upgraded Albertsons (ACI) to a Buy rating, raising its 12-month price target to $27 from $22, which represents a 35% potential upside from current levels. The upgrade is positioned as an opportunistic response to a recent 7% decline in the stock price, which UBS believes does not reflect the company's underlying strengths. The core of the bull thesis rests on three pillars: top-line growth, profitability enhancement, and competitive advantages. Top-line momentum is expected from the pharmacy business, which has recorded 15 consecutive quarters of double-digit growth and attracts customers who visit four times more frequently than non-pharmacy shoppers, alongside a growing digital channel. Profitability is projected to improve through centralized buying efficiencies, the expansion of the high-margin retail media business, and a clear path for private label goods to reach approximately 30% penetration from the current 25-26% level; every 100 basis point increase in private label penetration is estimated to support gross margins by about 10 basis points. Furthermore, ACI's strategic footprint in more densely populated and higher-income markets provides a durable competitive advantage, positioning it to gain market share as competitors reduce their physical store counts. UBS anticipates this will lead to consistent earnings beats, share repurchases, and a valuation re-rating that narrows the gap with its peer, Kroger (KR).

Key Decisions for Investors

• Investors could consider the recent share price weakness as a strategic entry point, aligning with the analyst's view that the pullback presents a disconnect with the company's fundamental opportunities.
• Monitor key performance indicators mentioned in the report, specifically pharmacy growth rates, progress in private label penetration towards the 30% target, and any resulting gross margin expansion, to validate the investment thesis.
• Watch for company announcements regarding its capital return policy, as the initiation or acceleration of a share repurchase program would serve as a key catalyst for the anticipated multiple re-rating and narrowing of the valuation gap with peers.